Clinical Trials
Radiation De-Escalation After Neoadjuvant Sintilimab and Chemotherapy in HNSCC
Qian et alNature communications

In an open-label phase 2 study (NCT05476965), investigators evaluated the efficacy of neoadjuvant chemo-immunotherapy (NACI) and its capacity to guide response-adapted postoperative radiotherapy or chemoradiotherapy (PORT/POCRT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Thirty patients with resectable stage III–IVB HNSCC received neoadjuvant sintilimab combined with chemotherapy, followed by surgical resection and response-stratified adjuvant therapy. The primary endpoint was the major pathologic response (MPR) rate, defined as 0% to 10% residual tumor. Secondary endpoints included overall survival (OS), disease-free survival (DFS), objective response rate (ORR), and adverse events.
Patients achieving an MPR were assigned to low-dose PORT (0–54 Gy), whereas patients without an MPR received standard-dose PORT or POCRT. The overall MPR rate was 59.1% (38.7%–76.7%). Patients in the MPR low-dose group had higher 2-year OS (100% vs. 77.8%) and 2-year DFS (100% vs. 55.6%) compared with the non-MPR standard-dose cohort, as well as fewer radiotherapy-related adverse events (all P < 0.05). The findings indicate that adaptive radiation de-escalation based on neoadjuvant chemoimmunotherapy response maintains survival outcomes while reducing treatment toxicity in LA-HNSCC.
Key Takeaways
- In resectable stage III–IVB locally advanced head and neck squamous cell carcinoma, neoadjuvant sintilimab plus chemotherapy achieved a major pathologic response (0–10% residual tumor) rate of 59.1% (38.7%–76.7%).
- Patients with a major pathologic response who underwent low-dose postoperative radiotherapy (0–54 Gy) achieved higher 2-year overall survival (100% vs. 77.8%) and 2-year disease-free survival (100% vs. 55.6%) alongside fewer radiotherapy-related adverse events compared with the non-response standard-dose group (all P < 0.05).
Read the original sourceNature communications
